UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 4, 2015
RICH PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| NEVADA | 000-54767 | 46-3259117 | ||
|
(State or other jurisdiction of incorporation or organization) |
Commission file number |
(IRS Employer Identification No.) |
9595 Wilshire Blvd, Suite 900
Beverly Hills, CA 90212
(Address of principal executive offices)
(323) 424-3169
(Registrant’s telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 8.01 OTHER EVENTS
As previously disclosed, Biosuccess Biotech, Co. LTD. (“Biosuccess”) filed a complaint against Rich Pharmaceuticals, Inc. (the “Company”), Imagic, LLC, Richard L. Chang’s Holdings, LLC, Richard Chang and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “Federal Court”). The complaint included allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, Richard Chang and Ben Chang (the “Litigation”).
The Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation is now in the process of being dismissed with prejudice by the Federal Court.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| RICH PHARMACEUTICALS, INC. | ||||||||
| Dated: January 4, 2015 | By: | /s/ Ben Chang | ||||||
|
Ben Chang Chief Executive Officer | ||||||||
| 2 |